# Clinical Trials Data EGFR - Document 77

# Study of Skin Toxicity of Cetuximab: Find a Link Between Skin Inflammation and Tumor Response

## Clinical Trial: https://clinicaltrials.gov/study/NCT01292356

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Patients older than 18 years\n\* Patient with histologically proven metastatic colorectal cancer with KRAS wild-type\n\* Treatment with cetuximab in first line chemotherapy combined with FOLFOX or FOLFIRI\n\* Patient has signed informed consent\n\* Patient affiliated to the Social Security\n\* Prescription of cetuximab in agreement with the Summary of Product Characteristics\n\nExclusion Criteria:\n\n\* Patients aged under 18\n\* Patients taking immunosuppressive therapy\n\* Patient having a severe skin disease\n\* No measurable metastasis\n\* Patients with a contra-indication of cetuximab: hypersensitivity to cetuximab or to any excipients\n\* Severe alteration of respiratory or cardiac function or severe coronary disease\n\* Patients with contra-indication to chemotherapy FOLFOX and FOLFIRI\n\* Participation in another research protocol\n\* Patients not affiliated to the Social Security\n\* Hospitalized patients without consent\n\* Pregnant or nursing women, women of childbearing age with no effective contraception",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided eligibility criteria for the clinical trial, the patient's EGFR gene mutation status is not mentioned as an inclusion or exclusion criterion. The critical genetic component in these criteria is that the patient must have "KRAS wild-type" colorectal cancer. As there is no mention of EGFR mutation status in the inclusion or exclusion criteria, a patient with an EGFR gene mutation would still be eligible for the trial, provided all other inclusion criteria are met and none of the exclusion criteria apply. It would be advisable for the patient or their healthcare provider to confirm eligibility with the trial organizers if there are any concerns.